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Introduction
Western populations are currently undergoing a 
major demographic shift as birth rates decline and 
survival into old age increases. The elderly therefore 
constitute an increasing proportion of the general 
population, and doctors are more and more likely to 
encounter octogenarians or even nonagenarians in 
their daily practice. Medical management of the very 
elderly (over 80 years) is often challenging, and one 
of the clinical conundrums that the clinician is very 
likely to face is management of dyslipidaemia and 
cardiovascular risk in octogenarians. 
Even a cursory glance at the Framingham risk algorithm 
or the European System for Cardiac Operative Risk 
Evaluation (euroSCORE) charts makes it obvious that age 
is one of the strongest determinants of cardiovascular 
risk. Absolute cardiovascular risk increases progressively 
with age and is highest in the very elderly population 
segment. More than 80% of all cardiovascular disease 
(CVD) -related deaths in the USA occur in those over 
65, and the prevalence of CVD in those above 80 
years of age is estimated to be 79% in men and 85% 
in women.1 Octogenarians only account for 5% of the 
USA population, but 20% of myocardial infarction (MI) 
and 30% of MI-related hospital deaths occur in this 
group.2 Because absolute cardiovascular risk is highest 
in octogenarians, statin therapy could potentially 
achieve large reductions in absolute risk. This prediction 
is based on the premise that the relative risk reduction 
seen in statin-treated patients is independent of age. 
This is not an unreasonable assumption, but there is little 
randomised clinical trial evidence of statin therapy in 
those above 80 years of age that conclusively proves 
the case.
Although octogenarians may therefore potentially 
benefit significantly from statin therapy, epidemiological 
surveys show that statin use declines with age and is 
lowest in those at highest risk.3 This finding has been 
described as the treatment-risk paradox. 
Age-related changes in lipoprotein metabolism
Mean plasma low-density lipoprotein cholesterol (LDL-C) 
rises with age. In men LDL-C plateaus around the age of 
50 years. In women LDL-C plateaus on average 10 years 
later than in men.4 After the age of 60 years, mean 
LDL-C is higher in women than in men, with menopausal 
hormonal changes contributing to the higher LDL-C 
observed in women. Mechanistically LDL-C rises in 
older individuals because of a decreased LDL-C 
fractional catabolic rate, which is likely secondary to 
decreased hepatic LDL receptor expression.5 High-
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density lipoprotein cholesterol (HDL-C) remains higher 
in women than in men, irrespective of age. Ageing 
is also associated with an increase in body fat, with 
the visceral adipose tissue compartment expanding 
most.6 Excess release of free fatty acids from visceral 
adipocytes, together with a decrease in the oxidative 
capacity of tissues, may lead to insulin resistance, 
increased generation of very low-density lipoproteins 
(VLDL) and ultimately an atherogenic lipid profile 
characterised by mild hypertriglyceridaemia, low 
HDL-C and small dense LDL particles. 
Occasionally the diagnosis of a monogenic 
dyslipidaemia, such as familial hypercholesterolaemia 
(FH), may be made for the first time in old age. 
Premature CVD is very common but not universal in 
FH. Although asymptomatic patients diagnosed late 
in life with FH have demonstrated relative “resistance” 
against atherosclerotic complications, one cannot 
assume that they are fully protected and treatment 
should still be considered. The children of such patients 
are likely to be adults, with correspondingly high risk if 
they have inherited the mutation, and family screening 
should form part of the therapeutic plan. 
Secondary causes of dyslipidaemia should also be 
considered in the elderly presenting with dyslipidaemia. 
The prevalence of hypothyroidism increases with age, 
and the manifestations may initially be subtle and 
easily overlooked; thyroid-stimulating hormone (TSH) 
should be measured before lipid-lowering therapy 
is considered. Other potential causes of secondary 
dyslipidaemia include medications, as well as renal 
and hepatic disease. 
Dyslipidaemia and cardiovascular risk in the 
elderly
The relative importance of hypercholesterolaemia 
in predicting cardiovascular risk decreases in 
the elderly, as age progressively becomes the 
dominant cardiovascular risk factor. However, 
hypercholesterolaemia does remain predictive of 
cardiovascular risk, at least in the 60-70-year age 
group, as data from the Framingham study show.7 
Initial studies in the very elderly suggested that there 
may be a U-shaped relationship between total 
cholesterol and cardiovascular risk and that low 
cholesterol values are associated with increased 
cardiovascular risk. Adjusting the data for markers of 
frailty and malnutrition, such as serum iron and albumin, 
abolishes this relationship.8 Low cholesterol values in the 
elderly therefore most likely reflect frailty, poor nutrition, 
chronic disease and possibly congestive cardiac 
failure, all conditions associated with a poor outcome. 
Hypercholesterolaemia in patients well advanced in 
age therefore remains predictive of cardiovascular 
risk, while low cholesterol coupled with frailty or chronic 
disease may be a poor prognostic sign. 
The treatment-risk paradox
Although cardiovascular risk is highest in the elderly, 
epidemiological surveys consistently show that statin 
prescription decreases with age. High risk therefore 
does not translate to a high probability of being 
treated. A Canadian registry data survey found that 
the adjusted likelihood of being prescribed a statin 
decreased by 6.4% for each year of age and was 
lower in high-risk patients than in low-risk patients.3 In 
an Italian study of patients discharged from hospital 
following an admission for ischaemic heart disease 
(IHD), it was found that patients older than 75 years 
were 40% less likely to be prescribed a statin than 
younger patients.9 The treatment-risk paradox is not 
specific to statins, and the elderly are also less likely to 
be offered interventional therapies, thrombolysis or β 
blockers, to name only a few examples. 
Possible explanations for the treatment-risk 
paradox
Safety concerns
The elderly, and especially the very elderly, are at 
high risk of developing drug-related adverse effects. 
Factors such as decreased drug metabolism, altered 
volumes of distribution, decreased physiological 
reserve and altered pharmacodynamics all play a 
role.10 Polypharmacy is very common in the elderly 
and may contribute further to the risk of drug-related 
adverse effects. The risk of drug-drug interactions rises 
exponentially with the number of prescribed drugs. 
The most common adverse effect of statins is 
myotoxicity, which may range in severity from mild 
myalgia to potentially fatal rhabdomyolysis. The 
risk of developing statin-related muscle problems 
rises with age. Cerivastatin-related muscle toxicity, 
for instance, was particularly common in elderly 
women with low body mass.11,12 However, this drug is 
now no longer on the market. The risk of myotoxicity 
may be increased by commonly prescribed drugs 
such as amiodarone, verapamil or macrolides that 
inhibit hepatic cytochrome p450 3A4 (CYP3A4) statin 
metabolism. Not all statins utilise CYP3A4, and the risk 
of drug-drug interactions can vary widely amongst 
statins. An example of a clinically relevant risk is the 
recent warning by the Federal Drug Administration 
regarding the risk of myopathy in patients on simvastatin 
and calcium-channel blockers or amiodarone. In 
octogenarians, where polypharmacy is the rule rather 
than the exception, statins are not all “created equal” 
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and the risk of drug-drug interactions should be a major 
consideration when choosing a statin. Co-prescription 
of fibrates with statins and high-dose statin therapy are 
also associated with an increased risk of myopathy. 
Statin therapy is associated with a small but statistically 
significant increase in the incidence of diabetes. This 
effect is most marked in trials enrolling predominantly 
older patients. Overall the estimated benefit of statin 
therapy outweighs potential deleterious effects related 
to new-onset diabetes, but the risk of diabetes should 
be considered when low-risk elderly patients are started 
on statins for primary prevention.13
There has been concern that statins may increase the 
risk of cancer in the elderly. This concern stems from the 
25% increased cancer incidence observed in the active 
treatment arm of the PROspective Study of Pravastatin 
in the Elderly at Risk (PROSPER), in which patients aged 
70-82 years were randomised either to pravastatin 
(40 mg per day) or to a placebo.14 The study authors 
attributed the increased cancer incidence to chance, 
and a subsequent meta-analysis of all major statin 
studies also found no link between statins and cancer.15 
In a large Swedish registry study of octogenarian MI 
survivors, the incidence of cancer was also not higher 
in those prescribed a statin at hospital discharge.16
Statins are thus often withheld in the elderly, the very 
elderly, because of safety concerns. The physician 
may also attempt to avoid polypharmacy and use 
as few drugs as possible. Statins offer little immediate 
benefit or symptom relief and are often regarded as 
expendable. 
Limited evidence base
The elderly, and especially the very elderly (over 80 
years), are not well represented in statin trials. All 
statin studies thus far have used age as an exclusion 
criterion. The upper age limit varies among trials 
but has usually been around 65-75 years with only a 
few trials enrolling older patients. Trials often exclude 
patients with comorbidities such as renal, cardiac or 
hepatic dysfunction and may not be applicable to an 
elderly population with a high prevalence of multiple 
comorbidities. Uncertainty regarding the risk-benefit 
ratio of statin therapy in the elderly may result in the 
withholding of statins. 
Evidence base for statin prescription in the 
elderly
This section presents selected evidence for the 
prescription of statins in the elderly and does not 
review the available literature comprehensively. More 
detailed reviews may be found under References.17-21 
Patients aged 65-82 years
A recent meta-analysis identified nine studies that 
had randomised patients older than 65 years with 
documented IHD at baseline (secondary prevention) 
to either placebo or statins for at least six months with 
assessment of clinical outcome variables.22 Of the 
nine studies analysed, PROSPER was the only study 
that specifically only recruited older subjects.14 For the 
other studies, investigators were contacted to provide 
data for elderly subgroups, which were unpublished in 
many cases. Data were analysed utilising hierarchical 
Bayesian modelling. 
The meta-analysis included 19 569 patients. About 
a quarter of the patients were female. Patients were 
65-82 years old at enrolment. Statin therapy was 
associated with a 22% relative risk reduction in all-
cause mortality [relative risk (RR) 0.78, 95% confidence 
interval (CI) 0.65-0.89]. IHD mortality was reduced 
by 30% (RR 0.70, 95% CI 0.53–0.83) and stroke was 
reduced by 25% (RR 0.75, 95% CI 0.56–0.94).22 This meta-
analysis therefore confirms that statins are effective in 
secondary-prevention patients aged 65–82 at the time 
of statin initiation. 
Statins as primary preventive therapy in the elderly 
have not been studied as extensively as statins in 
secondary prevention. The PROSPER study included 
primary-prevention patients with additional risk factors 
such as smoking, hypertension or diabetes. In a post-
hoc subanalysis, the risk reductions seen in the primary-
prevention group were not statistically significant in 
their own right, but the statistical test for interaction 
between the primary- and secondary-prevention 
subgroups was negative, suggesting that the failure to 
achieve statistically significant results may have been 
due to a lack of statistical power. In the Air Force/Texas 
Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS) of lovastatin as primary prevention in subjects 
with low HDL-C, 22% of the 6 605 participants were aged 
65-73 years at enrolment. In this subgroup, lovastatin 
was associated with a 37% reduction in major coronary 
events.23 
Octogenarians
Very few randomised statin studies have included 
significant numbers of octogenarians. The PROSPER 
trial had an age cut-off of 82 years, but the mean 
age of participants at enrolment was 75 years.14 The 
Study Assessing Goals in the Elderly (SAGE) enrolled 
participants aged 60-85 years with documented 
IHD and at least one episode of ischaemia lasting a 
minimum of three minutes on a 48-hour ambulatory 
electrocardiogram. Patients were randomised to either 
atorvastatin 80 mg daily or pravastatin 40 mg daily. The 
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primary efficacy parameter of total ischaemia duration 
was significantly reduced in both groups with no 
significant differences between the treatment groups. 
The all-cause mortality was lower in the intensive 
treatment group (atorvastatin 80 mg/day) with a trend 
towards fewer major acute coronary events. However, 
the mean age at enrolment in this study was 72 years 
and the authors do not report results for those over 80 
separately.24
In a recently published study, Gränsbo et al analysed 
data from the Register of Information and Knowledge 
About Swedish Heart Intensive Care Admissions (RIKS-
HIA).16 The registry had complete data for 14 907 patients 
that were 80 years or older when admitted to hospital 
with an acute MI. Patients were followed for a median 
of 296 days and all-cause mortality, cardiovascular 
mortality and cancer mortality were analysed. Analysis 
was by statin prescription at discharge. Statin therapy 
was associated with a marked reduction in all-cause 
mortality (RR 0.55, 95% CI 0.51-0.59) and cardiovascular 
mortality (RR 0.55, 95% CI 0.51-0.60). This mortality 
reduction was attenuated when patients that survived 
less than a year were excluded from the analysis. In 
patients that survived for at least a year postdischarge, 
the reduction in all-cause mortality was 36% (RR 0.64, 
95% CI 0.57-0.73) and the reduction in cardiovascular 
mortality was 39% (RR 0.61, 95% CI 0.52-0.72). 
These non-randomised nature of registry studies 
requires that these results be interpreted with caution. 
One of the greatest problems of registry studies is 
allocation bias: baseline factors associated with 
prognosis may also influence the likelihood of statin 
prescription. Results can be statistically adjusted for 
this using a propensity score, as was done in the study 
by Gränsbo et al, but unknown confounders may 
remain. Physicians likely withheld statins if they thought 
patients had poor life expectancy or poor quality of 
life, with little to be gained from statin therapy. Such 
treatment decisions would skew outcome in favour 
of statin-treated patients and lead to the unusually 
large risk reduction observed in the complete cohort. 
The relative risk reduction observed in patients that 
survived for at least one year thus probably comes 
closest to the risk reduction one may have found in a 
randomised study. Although the data supporting statin 
use in octogenarians are limited and come almost 
exclusively from secondary-prevention patients, the 
totality of evidence does suggest that the relative risk 
reduction achieved in octogenarians does not differ 
substantially from that observed in younger patients. 
Heart failure
Heart failure is a common problem in the elderly, and 
the role of statins in heart failure has been controversial. 
Some authors have voiced concerns that statins may 
cause or aggravate heart failure as they lower serum 
ubiquinone levels (co-enzyme Q10) with subsequent 
impairment of myocardial contractility.25 In advanced 
heart failure, low cholesterol is associated with worse 
outcomes but low cholesterol is likely a marker of 
frailty and advanced disease in this setting.26,27 The 
Controlled Rosuvastatin Multinational Study in Heart 
Failure (CORONA) randomised patients over the age 
of 60 (mean age 73 years) with systolic heart failure 
to rosuvastatin 10 mg or a placebo. Rosuvastatin 
did not reduce mortality or coronary events but did 
reduce cardiovascular hospitalisations.28 Importantly, 
treatment with rosuvastatin did not increase mortality 
or worsen heart failure in this group. 
The most important role of statins with regard to heart 
failure is probably the prevention of heart failure 
secondary to ischaemic cardiomyopathy.29 Statins 
should not be started in patients with advanced heart 
failure (lack of efficacy), but many authors argue 
that they should not be discontinued in patients with 
known coronary artery disease that develop heart 
failure, especially if the heart failure is not severe.30 It is 
important to remember that most of these conclusions 
are drawn from studies that included no or very few 
octogenarians. 
Hypertriglyceridaemia 
As shown above, there are limited data that support 
statin prescription in octogenarians with the primary 
therapeutic aim of cardiovascular risk reduction and 
LDL-C as the primary lipid target. The management of other 
lipid phenotypes in octogenarians is largely empirical 
and extrapolated from experience in younger patients 
as none of the relevant trials enrolled octogenarians. 
Severe hypertriglyceridaemia (triglycerides in excess 
of 10-15 mmol/l) may cause acute pancreatitis and 
after correction of secondary factors, fibrates may 
be necessary. Fibrates are mainly excreted renally 
and dosing should take into account that glomerular 
filtration rate is often reduced in the elderly. 
Cognitive function
Because hypercholesterolaemia in middle age is a risk 
factor for dementia and cognitive impairment in old 
age, it has been hypothesised that statin therapy may 
have the potential to improve cognitive outcomes 
in octogenarians.31 Statins could protect the brain 
by reducing the risk of vascular disease and strokes, 
but could also exert a direct effect, as high serum 
cholesterol has been shown to associate with lower 
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levels of β-amyloid in the cerebrospinal fluid and more 
β-amyloid deposition in the brain.32,33 
Many cross-sectional and case-control studies have 
found improved cognitive outcomes in statin-treated 
patients.34-37 However, other studies, especially those of 
longer duration, have failed to confirm these results.31,38 
Some studies have suggested that statins only slow 
the rate of decline of cognitive function in cognitively 
healthy individuals, while patients with mild cognitive 
impairment at baseline do not benefit.39 All these non-
randomised studies may be affected by prescription 
bias, as statin prescription rates are likely to be lower in 
those with even mild cognitive impairment at baseline. 
There may also be unrecognised confounders such 
as social class or baseline intelligence, both of which 
correlate with the risk of developing dementia and 
the likelihood of being prescribed a statin. Cognitive 
outcome has not been an endpoint in most of the 
major randomised statin studies, but was assessed in 
the Heart Protection Study (HPS) and PROSPER. In the 
HPS, cognitive function was assessed at the end of the 
study by means of a single telephonic questionnaire, 
and randomisation to simvastatin was not associated 
with a lower incidence of dementia.40 In the PROSPER 
study, cognitive function was assessed repeatedly 
during the study (at six time points) using four different 
neuropsychological tests. Cognitive function declined 
in both treatment groups, but there was no difference 
in the rate of decline between the pravastatin and 
placebo groups.41 A recent Cochrane meta-analysis 
identified three randomised trials of statin therapy in 
patients with established Alzheimer-type dementia. 
Statin therapy was not associated with improved 
cognition or functioning, although the results of one 
large randomised trial were still outstanding.42 
Conclusion
Cardiovascular risk is very high in octogenarians, and 
statin therapy has the potential to reduce absolute 
cardiovascular risk substantially. However, physicians 
are less likely to prescribe statins to octogenarians 
than to younger patients despite the higher risk in the 
former group. Much of the reluctance to prescribe 
statins stems from a lack of evidence and therapeutic 
uncertainty. Although the evidence base for using 
statins in octogenarians is limited, there is conclusive 
evidence that the therapeutic benefit of statin therapy 
for secondary prevention is similar in those under 65 
and the 65–82-year age group. More limited evidence 
suggests that relative risk reductions of comparable 
magnitude may be achievable in even older patients, 
especially in the setting of secondary prevention. 
It is unlikely that the large, randomised, placebo-
controlled clinical outcome trial that would finally 
prove the benefit of statins in octogenarians will be 
conducted in the near future, or ever. Statin prescription 
in octogenarians requires clinical judgement in 
assessing factors such as biological vs. chronological 
age, estimated life expectancy, quality of life, co-
morbidities and the ability of the patient to take 
medication safely. Laboratory screening for renal, liver 
and thyroid dysfunction should be performed prior to 
statin initiation. If the patient is taking other medications, 
these should be carefully assessed for possible drug-
drug interactions and the statin least likely to lead to 
interactions should be chosen. Statin therapy should be 
initiated at low doses with careful titration. Patients and 
their families should be given realistic expectations of 
what to expect from statin therapy. Preservation of or 
even improvements in cognitive function are currently 
not evidence-based indications for statin therapy, and 
one should not create false expectations in this regard. 
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